Oral islatravir once-monthly for HIV pre-exposure prophylaxis in cisgender women at high risk of HIV-1 infection

Phase 3, randomised, double-blind trial of islatravir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (4 arms), sponsored by MSD. Primary endpoints: Confirmed HIV-1 infection and Adverse events and adverse events leading to discontinuation. Status: unknown.